Skip to main content

Table 2 Pathological Paraments of Gastric Cancer Patients Underwent HIPEC

From: Hyperthermic intraperitoneal chemotherapy for patients with gastric cancer based on laboratory tests is safe: a single Chinese center analysis

Pathological paraments

 

Tumor size, cm

6.18 ± 3.08

Borrmann classification

 

 Type-I

4 (6%)

 Type-II

8 (13%)

 Type-III

12 (19%)

 Type-IV

14 (22%)

 Unknown

25 (40%)

WHO classification

 

 Adenocarcinoma

55 (87%)

 Others

7 (11%)

 Unknown

1 (2%)

Signet ring cell carcinoma

 

 Yes

24 (38%)

 No

37 (58%)

 Unknown

2 (4%)

Differentiation

 

 Poor

43 (68%)

 Poor-medium

12 (19%)

 Medium

3 (5%)

 Unknown

5 (8%)

Lauren classification

 

 Intestinal type

12 (19%)

 Diffuse type

21 (33%)

 Mixed type

11 (18%)

 Unknown

19 (30%)

Nerve invasion

 

 Yes

46 (73%)

 No

5 (8%)

 Unknown

12 (19%)

Vascular invasion

 

 Yes

41 (65%)

 No

10 (16%)

 Unknown

12 (19%)

T Stage

 

 T3

7 (11%)

 T4

29 (47%)

 ypT1a

2 (3%)

 ypT2

1 (1%)

 ypT3

2 (3%)

 ypT4

14 (22%)

 Unknown

8 (13%)

N Stage

 

 N0

4 (7%)

 N1

1 (1%)

 N2

11 (13%)

 N3

20 (33%)

 ypN0

5 (8%)

 ypN1

3 (6%)

 ypN2

3 (6%)

 ypN3

7 (11%)

 Unknown

9 (15%)

M Stage

 

 0

40 (65%)

 1

20 (32%)

 Unknown

3 (6%)

TNM Stage

 

 Stage I

3 (6%)

 Stage II

2 (3%)

 Stage III

37 (58%)

 Stage IV

19 (30%)

 Unknown

2 (3%)

Detected lymph nodes number

36 ± 17.66

Positive lymph nodes number

11.89 ± 14.99

AFP

 

 Positive

0 (0%)

 Negative

32 (51%)

 Unknown

31 (49%)

GPC3

 

 Positive

2 (3%)

 Negative

28 (45%)

 Unknown

33 (52%)

SALL4

 

 Positive

5 (8%)

 Negative

26 (41%)

 Unknown

32 (51%)

Her2

 

 Negative

29 (46%)

 + 

14 (22%)

 2 + 

2 (3%)

 3 + 

1 (2%)

 Unknown

17 (27%)